E-mail us:
service@prospectnews.com
Or call: 212 374 2800
Bank Loans - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
Add to balance / Manage account
Not logged in
Prospect News home
>
Main news index
>
All issuers starting with C
>
Issuers starting with C, HY only
>
All stories on Covis Finco Sarl
>
Stories on Covis Finco Sarl, HY only
Search again
Enter part or all of the issuer name:
Market:
All markets
No structured products
Bank loans
Canadian bonds
CLOs
Convertibles
Distressed debt
Emerging markets
High yield
Investment grade
Liability management
Municipals
PIPEs
Preferreds
Private placements
All leveraged markets
Structured products
Market: BK = Bank loans, CV = Convertibles, DD = Distressed Debt, EM = Emerging Markets, HY = High Yield, IG = Investment Grade, LM = Liability Management, MU = Municipals, PP = PIPEs, PF = Preferreds, PV = Private Placements, SP = Structured Products
Recent items, highlighted in orange, are $4.00 each.
All others are $1.00 each. Headlines in
gray
are not currently covered by your subscription.
Covis Finco Sarl
2/7/2022
HY
Covis Pharma withdraws $350 million equivalent euro-denominated secured notes
2/4/2022
HY
Covis Pharma delays syndication effort on $350 million equivalent bonds amid weak demand
2/4/2022
BKDDHY
Moody's rates Covis loan Caa1
1/31/2022
HY
Market Commentary:
Calendar builds; secondary firms; Bausch, Embecta improve; Athena struggles continue
1/31/2022
HY
Covis trims secured bond offering to $350 million equivalent, drops $475 million tranche
1/27/2022
HY
Market Commentary:
Junk primary has biggest session year to date; secondary trading ‘ugly’ as selling accelerates
1/25/2022
HY
Market Commentary:
ION on tap; junk secondary weaker; Oxford outperforms; Medline gains; Netflix active
1/21/2022
BKHY
Moody's assigns B2 to Covis notes
1/20/2022
HY
Covis Pharma sets initial price talk in $850 million equivalent two-part secured notes offering
1/19/2022
BKHY
S&P assigns B to Covis notes
1/19/2022
HY
Covis Pharma sets roadshow for $850 million equivalent two-part notes offer; investor call Thursday
©2025 Prospect News. This page is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies, faxing, photocopying or any other form of reproduction.
